Industry News: Pantec Biosolutions Announces Research Agreement with Takeda toInvestigate New Approaches for Inflammatory Skin Disease

08 May 2014


Pantec Biosolutions AG, the manufacturer of P.L.E.A.S.E.® Professional, a portable laser device for the precise microporation of the skin, has signed a research agreement with the New Frontier Science group at Takeda Pharmaceutical Company, Ltd. for the development of potential new treatments for inflammatory skin disease.

The agreement and new project idea involve the investigation of the potentially synergistic combination of Pantec’s P.L.E.A.S.E.® (Precise Laser Epidermal SystEm) device with topical drug formulations, with the goal of rapid and painless treatment of inflammatory skin disease in a target oriented way that avoids systemic exposure.

Through the companies’ collaboration with a world-class transdermal science team and a leading research oriented dermatologist, who will act as a principal investigator in a clinical trial, planned by Pantec Biosolutions, both partners believe that the new therapy may have the potential to improve the treatment of inflammatory skin disease.

Dr. Christof Boehler, member of the Board of Directors at Pantec Biosolutions and responsible for corporate business development, said: “We are excited to be working with Takeda to use our P.L.E.A.S.E. technology to investigate this innovative approach to the treatment of skin diseases. This project has will leverage the design features of the P.L.E.A.S.E. technology, namely the rapid, controlled and precise delivery of drugs for topical or intracutaneous applications.”

Pantec is currently attending the CIMT (Cancer Immunotherapy) annual meeting in Mainz, Germany with the goal of educating the immunology community about the stimulating effect of the laser microporation followed by precise delivery of immunogens to the epidermal and dermal dendritic cells.